FDA eCTD 4.0 Forward Compatibility Notice Lawsuit

The Food and Drug Administration announced support for Forward Compatibility for Electronic Common Technical Document (eCTD) Version 4.0-based electronic submissions, effective October 16, 2026. The announcement appears as a Notice in the Federal Register at 91 FR 65752. It covers the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. FDA states that comments may be submitted at any time.

At a glance

• FDA published the Notice at 91 FR 65752 on October 16, 2026, spanning pages 65752 and 65753.
• The action is titled “Electronic Common Technical Document (eCTD); Data Standards; Supporting Forward Compatibility for eCTD 4.0.”
• The Notice is filed under Docket No. FDA-2018-D-1216, whose docket title is “CDER Level 2 Technical Specifications Guidances.”
• FDA support for Forward Compatibility for eCTD v4.0 electronic submissions begins October 16, 2026.
• FDA states that comments may be submitted in electronic or written form at any time.

What is eCTD and what did FDA announce?

The Electronic Common Technical Document, usually abbreviated eCTD, is the electronic format FDA’s drug and biologics centers expect for regulatory submissions. Version 4.0 is a later iteration of that format than the versions in prior use, though the Notice itself does not describe the technical differences between versions.

What the Notice does is narrower than a rule. FDA’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research are “announcing support for Forward Compatibility for Electronic Common Technical Document (eCTD) Version 4.0 (v4.0)-based electronic submissions,” according to the agency’s abstract. That is an announcement of agency support, published as a Notice rather than a rule.

The Notice carries no Code of Federal Regulations references, according to the Federal Register metadata. It is two pages long, from page 65752 to page 65753 of volume 91.

What is established vs. what is alleged

There is no allegation in this document. The Notice is FDA’s own statement of its position, not a dispute between parties.

What is established by the record is that FDA published the Notice on October 16, 2026, under the document number 2026-21197, and that it announces support for Forward Compatibility for eCTD v4.0-based electronic submissions beginning that date. The agency, the docket and the date are all stated on the face of the Federal Register entry.

What is not established is anything beyond the announcement itself. The Notice does not, in the record supplied, set out technical specifications, a compliance deadline, an enforcement position, or a process for rejecting submissions that do not use the format.

Where the eCTD notice sits procedurally

This is a regulatory notice, not litigation, so there is no consolidation, no bellwether trial (a test trial used to gauge how other cases may resolve) and no MDL (multidistrict litigation, a procedure that consolidates related federal cases before one judge). No court is involved in producing the Notice.

The relevant procedural markers are the Federal Register citation, 91 FR 65752, and Docket No. FDA-2018-D-1216. The docket entry is FDA-2018-D-1216-0028, and the associated comment period opened October 16, 2026, with no closing date listed. The docket record shows late comments permitted and zero comments posted at the time the metadata was captured.

FDA’s Dates field states that support begins October 16, 2026, and that comments may be submitted at any time. Readers interested in how FDA handles other published agency actions can review the current list of HHS-certified laboratories and the emergency clearance public information collection notice, which follow the same Federal Register publication pattern.

Key dates

• October 16, 2026: FDA publishes the Notice at 91 FR 65752, and agency support for Forward Compatibility for eCTD v4.0 electronic submissions begins.
• October 16, 2026: The comment window on docket entry FDA-2018-D-1216-0028 opens.
• November 5, 2026: Federal Register page-view data for the document is last updated, and the regulations.gov docket check is recorded.

What this does not establish

The Notice does not change any regulation. No Code of Federal Regulations section is cited in the Federal Register record for this document.

The record supplied does not state a deadline by which sponsors must move to eCTD v4.0. It does not state whether older versions remain acceptable, or for how long.

The record does not describe submission validation criteria, technical conformance requirements, or the consequences of a submission that lacks forward compatibility.

The record does not state how many submissions FDA has received in eCTD v4.0 format, nor any industry response to the announcement.

The record does not show that any comment has been filed. The regulations.gov entry lists a comment count of zero as of the recorded check.

Frequently asked questions

What did FDA announce about eCTD 4.0 in October 2026?

The Food and Drug Administration published a Notice at 91 FR 65752 on October 16, 2026, announcing support for Forward Compatibility for Electronic Common Technical Document Version 4.0-based electronic submissions. The announcement applies to the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. It is an announcement of support, published as a Notice rather than a rule.

Is the eCTD 4.0 notice a final rule?

No. The Federal Register classifies document 2026-21197 as a Notice, and the Federal Register record lists no Code of Federal Regulations references for it. The action described in the abstract is that FDA’s drug and biologics centers are announcing support for forward compatibility for eCTD v4.0-based electronic submissions. A Notice is a published agency statement; this one does not amend a regulation.

When does FDA support for eCTD 4.0 forward compatibility begin?

FDA’s Dates field states that support for Forward Compatibility for eCTD v4.0 electronic submissions begins October 16, 2026, the same day the Notice was published. The document appears in volume 91 of the Federal Register at pages 65752 and 65753. The Notice does not state an end date or a transition period for the format.

Can the public still comment on the eCTD 4.0 notice?

Yes. FDA states that comments may be submitted at any time, either electronically or in writing, through docket entry FDA-2018-D-1216-0028 under Docket No. FDA-2018-D-1216. The regulations.gov record shows no closing date and permits late comments. At the time of the recorded docket check, the comment count was zero.

Where is the notice published?

The Notice appears in the Federal Register, the daily publication of federal agency rules, proposed rules and notices, at 91 FR 65752 for October 16, 2026. The document number is 2026-21197, and the docket is FDA-2018-D-1216, titled “CDER Level 2 Technical Specifications Guidances.” Full text is available in HTML, PDF and XML formats from the Federal Register.

Sources

1. Federal Register (Food and Drug Administration): “Electronic Common Technical Document (eCTD); Data Standards; Supporting Forward Compatibility for eCTD 4.0” (link, accessed 2026-11-05)
2. Federal Register: “All Documents” (link, accessed 2026-11-05)